van de Vusse 2004

Methods	Randomised, double‐blind, placebo‐controlled, cross‐over, no enrichment Gabapentin titrated to maximum of 1800 mg daily over 5 days, then stable dose for remainder of 3‐week treatment period; 2‐week washout then cross‐over
Participants	Complex regional pain syndrome type 1 (IASP criteria for diagnosis). N = 58, mean age 44 years, 17% women. Pain duration before treatment > 3/10, initial pain intensity 6.3/10 46 patients completed both periods, with 12 excluded from analysis because they withdrew at some stage. Analysis performed only on complete data sets
Interventions	Gabapentin 1800 mg daily Placebo Usual analgesics continued without dose changes
Outcomes	Much improved (per protocol) Adverse events Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Low risk	"closed envelopes containing assignments were prenumbered and kept at the pharmacy"
Blinding (performance bias and detection bias) All outcomes	Low risk	"identical placebo capsules"
Incomplete outcome data (attrition bias) Efficacy	High risk	Analysis performed on completers
Size Efficacy	High risk	Only 46 in final analysis
Study duration Efficacy	Unclear risk	3‐week period
Outcomes reported	Unclear risk	Much improved